Sarepta Therapeutics, Inc. (SRPT) - Q1 2026 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 31, 2026. Sarepta Therapeutics is a commercial-stage biopharmaceutical company focused on rare diseases, primarily Duchenne muscular dystrophy (DMD). The company's portfolio includes PMO products (EXONDYS 51, VYONDYS 53, AMONDYS 45) and the gene therapy ELEVIDYS. The quarter was significantly impacted by the ongoing management of ELEVIDYS safety concerns, a strategic restructuring announced in July 2025, and major collaboration revenue recognition.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Total Revenues | $730.8 million | $744.9 million |
| Net Income (Loss) | $331.0 million | ($447.5 million) |
| Operating Income (Loss) | $358.4 million | ($300.4 million) |
| Diluted EPS | $2.88 | ($4.60) |
| Cash & Investments | $748.3 million | $953.8 million |
| Long-Term Debt | $838.2 million | $829.0 million |
| Net Cash Used in Operating Activities | ($202.7 million) | ($583.4 million) |
Material Changes vs. Prior Period
- Revenue Composition Shift: While total revenue remained relatively flat (-2%), the mix changed drastically. Product revenue declined 46% to $330.5 million, driven by a 73% drop in ELEVIDYS sales due to the suspension of shipments to non-ambulatory patients and label restrictions. Conversely, collaboration revenue surged 226% to $400.3 million, primarily due to a $325.0 million recognition from Roche declining an option and a $40.0 million milestone for ELEVIDYS commercial dosing in Japan.
- Profitability Turnaround: The company reported a net income of $331.0 million compared to a net loss of $447.5 million in Q1 2025. This swing was driven by a massive 80% reduction in R&D expenses (from $773.4M to $154.0M), largely due to the absence of the $583.6 million Arrowhead upfront license fee recognized in the prior year, and the significant collaboration revenue.
- Liquidity Position: Cash and cash equivalents decreased by $336.8 million to $464.5 million. Total cash, cash equivalents, and investments stood at $748.3 million. The company utilized its Revolving Credit Facility, drawing and repaying $250.0 million during the quarter.
Guidance, Outlook, Risks, and Unusual Items
- ELEVIDYS Safety & Regulatory Status: In November 2025, the company announced a boxed warning for acute liver injury/failure and removed the non-ambulatory population from the label. Shipments to ambulatory patients resumed in July 2025. The company is conducting a study using sirolimus to evaluate a pathway to resume dosing in non-ambulatory patients, pending FDA analysis.
- ESSENCE Trial Results: In November 2025, topline results for the ESSENCE confirmatory trial for VYONDYS 53 and AMONDYS 45 did not meet statistical significance on the primary endpoint. The company submitted supplemental NDAs in April 2026 but faces potential regulatory actions, including label changes or market withdrawal.
- Restructuring Impact: A strategic restructuring announced in July 2025 reduced the workforce by approximately 36% and suspended most LGMD programs (except SRP-9003). This contributed to lower operating expenses in Q1 2026.
- Legal Proceedings: The company is involved in significant patent litigation with Regenxbio/U-Penn regarding ELEVIDYS (Federal Circuit reversed a summary judgment in favor of Sarepta in Feb 2026) and Nippon Shinyaku (jury awarded Sarepta ~$115.2 million in damages in Jan 2025, with post-trial motions pending). A securities class action lawsuit regarding ELEVIDYS disclosures remains active.
- CEO Transition: CEO Douglas Ingram announced his intention to retire by the end of 2026 or upon the appointment of a successor.
Investor Verification Checklist
- ELEVIDYS Demand Forecast: Verify the sustainability of ambulatory patient demand following the label restriction and the timeline for potential resumption of non-ambulatory dosing.
- ESSENCE Trial Regulatory Path: Confirm the FDA's specific response to the failed ESSENCE trial results and the likelihood of maintaining market access for VYONDYS 53 and AMONDYS 45.
- Collaboration Revenue Recurrence: Assess the non-recurring nature of the $365 million Roche collaboration revenue recognized in Q1 2026 and its impact on future earnings guidance.
- Inventory Valuation: Review inventory levels ($1.18 billion total) for potential write-downs given the reduced demand for ELEVIDYS and the suspension of LGMD programs.
- Debt Covenants: Monitor compliance with the Revolving Credit Facility covenants (max secured net leverage ratio of 3.5:1.0) given the volatility in cash flows and potential future restructuring costs.